Pharma sector boosts FTSE

Bid talk in the pharma sector has given the FTSE 100 a post-Easter bounce, with the index kicking off the shortened week with an initial gain of 50 points.

Traders have stumbled back to their desks this morning after an indulgent long weekend of chocolate consumption. Whilst the economic day has gotten off to a slow start, there has been bid activity that has seen the premier index rise to its highest level in around two weeks. Last week’s price action witnessed a significant turnaround in market direction, as earnings season provided indices with the positive momentum needed to halt what had looked to be a wave of selling. 

Reports in the weekend press suggested Pfizer had been interested in UK pharma giant AstraZeneca. The news has propelled AstraZeneca to the top of the leaderboard this morning, with sector peers GlaxoSmithKline and Shire following along in its wake. AstraZeneca briefly revisited £41 a share this morning, the highpoint of its recent rally, but since then the shares have dropped back. However, the development pipeline of drugs that would come with any acquisition of AstraZeneca means Pfizer may not be easily deterred. A purchase of AstraZeneca would make sense for Pfizer, given an overseas acquisition would avoid the need to repatriate assets back to the US.

The pace of earnings reports becomes frenetically busy this week, with many major names updating the market. However, the big events will be Facebook and Apple, as the tech giants look to recover from the momentum selloff we witnessed before Easter.

US indices have staged an impressive bounceback from the mid-April lows, with the Dow Jones seemingly back on course to retarget previous highs. Ahead of the open, we expect the Dow to start 18 points lower at 16,431, after yesterday’s modest gains. 

This information has been prepared by IG, a trading name of IG Markets Limited. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients. See full non-independent research disclaimer and quarterly summary.

Find articles by analysts

Een artikel zoeken

Form has failed to submit. Please contact IG directly.

  • Ik wens per e-mail informatie van IG Group bedrijven te ontvangen over handelsideeën en IG's producten en diensten.

Voor meer informatie over hoe wij uw gegevens mogelijk kunnen gebruiken, bekijkt u ons Privacy- en toegangsbeleid en onze privacy website.

CFD’s zijn complexe instrumenten en brengen vanwege het hefboomeffect een hoog risico mee van snel oplopende verliezen. 79% van de retailbeleggers lijdt verlies op de handel in CFD’s met deze aanbieder.
Het is belangrijk dat u goed begrijpt hoe CFD's werken en dat u nagaat of u zich het hoge risico op verlies kunt permitteren.
CFD’s zijn complexe instrumenten en brengen vanwege het hefboomeffect een hoog risico mee van snel oplopende verliezen.